Editorial Expression of Concern: Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation
Xueyan Cao, Yang Yang, Wei Zhou, Yue Wang, Xue Wang, Xianxiu Ge, Fei Wang, Fangfang Zhou, Xueting Deng, Lin Miao · 2026
Read Editorial Expression of Concern: Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation by Xueyan Cao, Yang Yang, Wei Zhou, Yue Wang, Xue Wang, Xianxiu Ge, Fei Wang, Fangfang Zhou, Xueting Deng, Lin Miao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13397671.txt.
Description
Xueyan Cao and co-authors are named on a 2026 editorial notice flagging image problems in their 2023 gallbladder cancer paper in BMC Cancer. Editors warn readers that panels in two figures appear to overlap. The paper had claimed the anti-nausea drug aprepitant slows gallbladder cancer growth and spread through reactive oxygen species and MAPK signalling.
In figure 2B, panels labelled for different drug doses and times seem to share image content, and the same concern is raised for figure 3B. Readers are told to treat the results with caution while the record stands unresolved. All ten listed authors agreed to the notice, which the journal issued as an Expression of Concern rather than a retraction.
Catalog record
| CREATOR | Xueyan Cao, Yang Yang, Wei Zhou, Yue Wang, Xue Wang, Xianxiu Ge, Fei Wang, Fangfang Zhou, Xueting Deng, Lin Miao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 1453 |
| LICENSE | https://creativecommons.org/publicdomain/zero/1.0 |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |